

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣東康華醫療集團股份有限公司

GUANGDONG KANGHUA HEALTHCARE GROUP CO., LTD.*

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3689)

PROFIT ALERT

This announcement is made by Guangdong Kanghua Healthcare Group Co., Ltd. (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the Board’s preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2025 and information currently available to the Board, the Group is expected to record a profit ranging from RMB32.0 million to RMB33.0 million (the amount of which is still being finalised by the management) for the six months ended 30 June 2025 (the “**2025 Interim**”) as compared to the loss of approximately RMB24.7 million for the six months ended 30 June 2024.

The foregoing is primarily attributable to the Group’s disposal of 55% equity interest in Kangxin Hospital (please refer to the Company’s announcement dated 9 January 2025 for the definition and further details):

- As a result of the disposal (which was completed in February 2025), the Group is expected to record a gain on disposal of approximately RMB19.5 million for the 2025 Interim.

* For identification purposes only

- Kangxin Hospital has been loss-making continuously in past few years. Subsequent to the disposal, the financial results of Kangxin Hospital have been de-consolidated from those of the Group. The Group has accounted for its remaining 45% equity interest in Kangxin Hospital as “interest in associate” under the equity method and is expected to record a share of the loss of Kangxin Hospital of approximately RMB18.4 million for the 2025 Interim. The remaining 55% of the loss of Kangxin Hospital is not consolidated in the financial results of the Group for the 2025 Interim. Therefore the disposal had a net positive impact to the financial results of the Group, as compared to full consolidation of Kangxin Hospital’s loss prior to the disposal.

The Company is still in the process of finalising the results for the 2025 Interim. The information contained in this announcement is only based on the Board’s preliminary review of the unaudited consolidated management accounts of the Group for the 2025 Interim (which has not been audited by the auditors of the Company) and information currently available to the Board. It is expected that the Group’s interim results announcement for the 2025 Interim will be published on or before 29 August 2025. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Guangdong Kanghua Healthcare Group Co., Ltd.*
WANG Junyang
Chairman and Executive Director

Hong Kong
 20 August 2025

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. Wang Junyang (*Chairman*)
 Mr. Chen Wangzhi (*Chief executive officer*)
 Mr. Wong Wai Hung (*Vice chairman*)
 Ms. Wang Aiqin

Independent non-executive Directors:

Dr. Chen Keji
 Ms. Lam Shiu Ling Cecilia
 Mr. Chan Sing Nun

Non-executive Director:

Mr. Lv Yubo

* *For identification purposes only*